Because tacrolimus (Tac) has a narrow therapeutic index and highly inter- and intra-individual variable pharmacokinetic (PK) characteristics, monitoring of drug exposure is recommended, but limited data are available on the kinetics of Tac in paediatric renal transplant recipients, especially of limited sampling strategies. To investigate the correlation between Tac trough level (TL) and the 0–12 h area under the curve (AUC), and the value of abbreviated AUC monitoring, we evaluated 12 h PK profiles in 27 children at least 1 year after transplantation. There was a significant discrepancy between Tac TLs and 0–12 h AUC (r = 0.60). Every time point, different from C0, gave a better prediction for the drug exposure, with C4 and C6 as best predictors (r = 0.93 and r = 0.92, respectively). The 0–12 h AUC was estimated with great precision by the use of a two- or three-point sampling strategy, and the latter is more time-point independent. In paediatric renal transplant recipients on Tac maintenance therapy, whose condition is stable, Tac TL is not a reliable tool for the estimation of drug exposure. Abbreviated monitoring, especially at three points in time, give reliable predictions of the complete 0–12 h AUC. We suggest a 0–12 h AUC of around 150 ng × h/ml for stable paediatric renal transplant recipients 1 year after transplantation and around 100 ng × h/ml in the following years. Target AUC values should be further established for paediatric transplant recipients according to the time after transplantation.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Conley SB, Flechner SM, Rose G, Van Buren CT, Brewer E, Kahan BD (1985) Use of cyclosporine in pediatric renal transplant recipients. J Pediatr 106:45–49
Hardie IR, Tiller DJ, Mahony JF, Miach PJ, Thomson NM, Thatcher GN, Rigby RJ, Menzies BL (1993) Optimal combination of immunosuppressive agents for renal transplantation: first report of a multicentre, randomised trial comparing cyclosporine + prednisolone with cyclosporine + azathioprine and with triple therapy in cadaver renal transplantation. The Australian Collaborative Trials Committee. Transplant Proc 25:583–584
Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramman R, Jain A (1989) K 506 for liver, kidney, and pancreas transplantation. Lancet 2:1000–1004
Starzl TE, Fung J, Jordan M, Shapiro R, Tzakis A, McCauley J, Johnston J, Iwaki Y, Jain A, Alessiani M, Todo S (1990) Kidney transplantation under FK 506. JAMA 264:63–67
Wallemacq PE, Verbeeck RK (2001) Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin Pharmacokinet 40:283–295
Filler G, Webb NJ, Milford DV, Watson AR, Gellermann J, Tyden G, Grenda R, Vondrak K, Hughes D, Offner G, Griebel M, Brekke IB, McGraw M, Balzar E, Friman S, Trompeter R (2005) Four-year data after pediatric renal transplantation: a randomized trial of tacrolimus vs. cyclosporin microemulsion. Pediatr Transplant 9:498–503
Filler G, Grygas R, Mai I, Stolpe HJ, Greiner C, Bauer S, Ehrich JH (1997) Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants. Nephrol Dial Transplant 12:1668–1671
Lee MN, Butani L (2007) Improved pharmacokinetic monitoring of tacrolimus exposure after pediatric renal transplantation. Pediatr Transplant 11:388–393
Armendáriz Y, Pou L, Cantarell C, Lopez R, Perelló M, Capdevila L (2005) Evaluation of a limited sampling strategy to estimate area under the curve of tacrolimus in adult renal transplant patients. Ther Drug Monit 27:431–434
Op den Buijsch RA, van de Plas A, Stolk LM, Christiaans MH, van Hooff JP, Undre NA, van Dieijen-Visser MP, Bekers O (2007) Evaluation of limited sampling strategies for tacrolimus. Eur J Clin Pharmacol 63:1039–1044
Derksen-Lubsen G, Van Steensel-Moll HA, Visser HK (2006) Compendium kindergeneeskunde diagnostiek en behandeling. Bohn Stafleu Van Loghum, Houten, p 325
Kuypers D, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y (2007) CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 82:711–725
Staatz CE, Willis C, Taylor PJ, Tett SE (2002) Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther 72:660–669
Filler G, Feber J, Lepage N, Weiler G, Mai I (2002) Universal approach to pharmacokinetic monitoring of immunosuppressive agents in children. Pediatr Transplant 6:411–418
Kim JS, Aviles DH, Silverstein DM, Leblanc PL, Matti Vehaskari V (2005) Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients. Pediatr Transplant 9:162–169
Shishido S, Asanuma H, Tajima E, Honda M, Nakai H (2001) Pharmacokinetics of tacrolimus in pediatric renal transplant recipients. Transplant Proc 33:1066–1068
Webb NJ, Stevenson PJ, Lewis MA, Postlethwaite RJ, Bradbury MG, Undre NA (2002) Pharmacokinetics of tacrolimus in paediatric renal transplant recipients. Transplant Proc 34:1948–1950
Montini G, Ujka F, Varagnolo C, Ghio L, Ginevri F, Murer L, Thafam BS, Carasi C, Zacchello G, Plebani M (2006) The pharmacokinetics and immunosuppressive response of tacrolimus in paediatric renal transplant recipients. Pediatr Nephrol 21:719–724
Scholten EM, Cremers SC, Schoemaker RC, Rowshani AT, van Kan EJ, den Hartigh J, Paul LC, de Fijter JW (2005) AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int 67:2440–2447
Kelles A, Herman J, Tjandramaga TB, Van Damme-Lombaerts R (1999) Sandimmune to Neoral conversion and value of abbreviated AUC monitoring in stable pediatric kidney transplant recipients. Pediatr Transplant 3:282–287
Knight SR, Morris PJ (2007) The clinical benefits of cyclosporine C2-level monitoring: a systematic review. Transplantation 83:1525–1535
Jorgensen K, Povlsen J, Madsen S, Madsen M, Hansen H, Pedersen A, Heinsvig EM, Poulsen J (2002) C2 (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients. Nephrol Dial Transplant 17:1487–1490
Opelz G, Döhler B (2008) Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. Transplantation 86:371–376
Hesselink DA, Ngyuen H, Wabbijn M, Gregoor PJ, Steyerberg EW, van Riemsdijk IC, Weimar W, van Gelder T (2003) Tacrolimus dose requirement in renal transplant recipients is significant higher when used in combination with corticoids. Br J Clin Pharmacol 56:327–330
About this article
Cite this article
Claeys, T., Van Dyck, M. & Van Damme-Lombaerts, R. Pharmacokinetics of tacrolimus in stable paediatric renal transplant recipients. Pediatr Nephrol 25, 335–342 (2010). https://doi.org/10.1007/s00467-009-1331-6
- Paediatric renal transplantation
- Abbreviated AUC monitoring
- Limited sampling strategy